The new Humira?
It’s not that often that you see industry-sponsored head-to-head studies of one biologic vs. another, but Abbvie took the plunge comparing risankizumab (Skyrizi) to ustekinumab (Stela…
A first Covid-19 interventional study – unfortunately negative
The first of what promises to be a series of many interventional studies for acute Covid-19 disease to appear in the Journal. Lopinavir i…
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.
